CClinicalTrials.gg
Status unknownNCT03257488Updated Aug 22, 2017

Screening of Obstructive Sleep Apnea Syndrome in Patients With Resistant Systemic Arterial Hypertension: Pilot Study

An interventional study of type IV portable monitoring (Somnocheck micro Weinmann) in Sleep Apnea, Obstructive and Resistant Hypertension, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Status unknown at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-22.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates the utility and reliability of Somnocheck micro Weinmann for obstructive sleep apnea syndrome (OSAS) screening in patients affected by resistant systemic arterial hypertension. Results are compared with a modified portable sleep apnea testing (type III portable monitoring: Somnocheck 2 Weinmann).

Read the detailed description

OSAS is a syndrome characterized by the partial or total collapse of the high airways which determines snore, airflow limitation, hypopnea and apnea.These events cause desaturations, daytime sleepiness and an increased risk of cardio and cerebral vascular diseases.

OSAS's prevalence is estimated between 64-83% among patients affected by resistant arterial hypertension; therefore OSAS's screening is mandatory during the clinical work-up of these patients.

This study is a randomized, interventional, spontaneous, exploratory, cross-over and monocentric trial, which assesses the utility and reliability of the reduced cardio-respiratory monitoring (type IV portable monitoring: Somnocheck micro Weinmann) to estimate the prevalence of OSAS among patients affected by resistant systemic arterial hypertension. The results are compared with a complete cardio-respiratory monitoring (type III portable monitoring: Somnocheck 2 Weinmann).

02

Conditions studied

  • Sleep Apnea, Obstructive
  • Resistant Hypertension
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Resistant Arterial Hypertension
  • Patients must sign the informed consent

Exclusion Criteria: ,

  • atrial fibrillation with haemodynamic instability
  • congestive hearth failure,
  • BMI>45 kg/m2,
  • respiratory failure
  • renal or liver failure,
  • stroke,
  • implantable cardioverter-defibrillator (ICD),
  • pacemaker (PM),
  • previous diagnosis of OSAS,
  • pregnancy,
  • breastfeeding,
  • patients must not be already enrolled in other clinical trial.
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Screening device-Traditional device

    The patients included in the A Group will be studied during the first night with the screening device (type IV portable monitoring Somnocheck micro Weinmann) and with the traditional one during the following night.

    Device: type IV portable monitoring (Somnocheck micro Weinmann)

  • Active comparator
    Traditional device-Screening device

    The patients included in the B Group will be studied during the first night with the traditional device and with the screening one (type IV portable monitoring Somnocheck micro Weinmann) during the following night.

    Device: type IV portable monitoring (Somnocheck micro Weinmann)

Interventions

  • Devicetype IV portable monitoring (Somnocheck micro Weinmann)

    Somnocheck micro Weinmann: a screening device for sleep disorders assessment. Somnocheck 2 Weinmann: a diagnostic device for obstructive sleep apnea.

    Also known as: type III portable monitoring (Somnocheck 2 Weinmann)

05

What researchers measure

Primary outcomes

  1. Apnea hypopnea index (AHI) differences between screening device and the traditional diagnostic one.

    Apnea hypopnea index (AHI) differences between screening device and the traditional diagnostic one.

    Time frame: These two procedures must be done in the same patient within 5 days

Secondary outcomes

  1. Number of Participants with cardiovascular abnormalities 1

    Number of Participants with cardiovascular abnormalities assessed by arterial blood pressure monitoring

    Time frame: Cardiovascular assessment must be done within 6 months before the sleep studies.

  2. Number of Participants with cardiovascular abnormalities 2

    Number of Participants with cardiovascular abnormalities assessed by ecocardiography

    Time frame: Cardiovascular assessment must be done within 6 months before the sleep studies.

06

Study locations

1 of 1 sites recruiting
  • Azienda ospedaliera policlinico Sant'Orsola-Malpighi
    Bologna, 40138, Italy
    Recruiting
07

Registry details

Key details

Study ID
NCT03257488
Lead sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Responsible party
Francesco Tavalazzi (Medical Doctor, IRCCS Azienda Ospedaliero-Universitaria di Bologna) — Principal investigator
First posted
Aug 22, 2017
Start date
Apr 2015
Primary completion
Dec 2018 (estimated)
Completion
Feb 2019 (estimated)
Last update
Aug 22, 2017

Study contacts

Francesco Tavalazzi, Medical
Contact
francesco.tavalazzi@aosp.bo.it
+390512143253

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion